Nothing said here yet.
to join the conversation.
The consensus price target hints at an 82.8% upside potential for Silence Therapeutics (SLN).
Silence Therapeutics has surged into the spotlight after a sharp re-rating of its share price and a takeover agreement, which puts fresh focus on a simple question for investors.
Silence Therapeutics (NASDAQ:SLN) kicked off the trading week by more than doubling its share price, as investors snapped up its shares following Merck KGaA’s offer to acquire the company for a 130-percent premium.
Silence Therapeutics PLC (NASDAQ:SLN, FRA:XRP1, OTC:SLNCF), the clinical-stage biotechnology company, surged 59% to $6.11 after agreeing to a $1.3 billion takeover by Merck KGaA, the German pharmaceutical and technology group.
Investing.com -- Silence Therapeutics shares leapt more than 125% in premarket trading Monday after the company announced it has entered into a definitive agreement to be acquired by Germany’s Merck KGaA in an all-cash transaction.
LONDON, October 19, 2026--Silence Therapeutics plc (Nasdaq: SLN) ("Silence"), a biotechnology company developing precision engineered medicines using its proprietary siRNA technology, today announced that it has entered into a definitive agreement with Merck…
The heavy selling pressure might have exhausted for Silence Therapeutics (SLN) as it is technically in oversold territory now.
Silence Therapeutics (SLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LONDON, September 02, 2026--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the following conferences and…
LONDON, August 14, 2026--Silence Therapeutics plc, (Nasdaq: SLN), ("Silence" or the "Company"), a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced the closing of its previously announced…
LONDON, August 12, 2026--Silence Therapeutics plc ("Silence" or the "Company") , a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced that it has priced its previously announced underwritten public offering of 12,962,963 American Depositary Shares ("ADSs"), each representing three ordinary shares of £0.05 each in the capital of the Company, in the United States at a public offering price of $13.50 per ADS.
Silence Therapeutics (NASDAQ:SLN) reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its primary endpoint and supporting the company’s plan to advance a…